BWL
SYRS

Bogart Wealth LLC’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bogart Wealth LLC’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15
Closed – – 1214
2022
Q3 		$0 Buy
+15
New +$122 ﹤0.01% 1167
2022
Q2 		– Sell
-2
Closed – – 1000
2022
Q1 		$0 Hold
2
– – ﹤0.01% 875
2021
Q4 		$0 Hold
2
– – ﹤0.01% 838
2021
Q3 		$0 Buy
+2
New +$98 ﹤0.01% 794

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Bogart Wealth LLC's SYRS Position: Q4 2022 in Review

Bogart Wealth LLC sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2022, closing a stake of 15 shares.

Bogart Wealth LLC first reported a position in SYRS in Q3 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 57 funds tracked by Wall St. Rank hold SYRS as of Q4 2022.

  • Bogart Wealth LLC reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Bogart Wealth LLC sold 15 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Bogart Wealth LLC first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Bogart Wealth LLC's Syros Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q3 2022.
  • 57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Bogart Wealth LLC's 13F filing for Q4 2022, filed 6 Feb 2023.